History

2004

2004

•  Evive Biotech founded

2004
2005

2005

  • Filed the first patent for rhIL-22
2005
2007

2007

• Early development of therapeutic rhIL-22

2007

2008

  • Strategic partnership with PharMab and initiated
    F-627 project for the treatment of Neutropenia
2008
2009

2009

• Established DikineTM platform and initiated F-652 (rhIL-22 dimer) project

• Completed F-627 preclinical studies

2009

2010

  • Initiated and completed Ph I study for F-627
2010
2011

2011

•  F-627 CMO manufacturing in US

2011

2012

  • Received F-627 China IND approval
  • Initiated F-627 Ph II study in US and Europe
  • Launched cGMP manufacturing plant project

2012
2014

2014

• Established ITab platform
• Completed F-627 Ph II study in US and Europe
• Initiated F-627 China Ph II study

2014

2015

  • Initiated two Ph II studies in US for F-652 to treat patients with GvHD (acute graft versus host disease) and AH (acute alcoholic hepatitis)
  • Completed F-627 China Phase II study
  • Received F-652 China IND approval
  • Completed F-627 first GMP run
2015
2016

2016

• F-627 US Ph III IND approval
• Initiated F-627 Ph III study (04) in US and Europe

2016

2017

  • ITabTM platform China patent granted
  • F-627 SPA agreement with U.S. FDA
  • F-627 China Ph III IND approval
  • Filed China IND for A-319
  • Initiated A-337 Ph I study in patients in Australia
  • Completed F-652 China Ph I study
2017
2018

2018

• F-627 Ph III study (04) met primary and secondary end points
• Initiated F-627 second global Ph III study (05)
• Completed F-652 Ph IIa study to treat AH

2018

2019

  • Initiated Ph I trial A-319 to treat patients with B cell malignancies
  • Received Orphan-Drug Designation from U.S. FDA for F-652 for the treatment of Acute Graft vs Host Disease
2019
2020

2020

• F-627 China Ph III study met primary endpoints
• Completed F-652 Ph IIa study to treat GvHD
• F-627 second global Ph III study (05) met primary endpoints
• Rebranded Generon to Evive Biotech

2020